Alcon

News
eye

Novartis/Ophthotech eye combo fails in phase 3

Novartis and Ophthotech's pegpleranib has flopped in two phase 3 trials, failing to improve efficacy when added to the Swiss pharma’s Lucentis in neovascular age-related macular degeneratio